BR112019000837A2 - células miméticas de célula b - Google Patents

células miméticas de célula b

Info

Publication number
BR112019000837A2
BR112019000837A2 BR112019000837A BR112019000837A BR112019000837A2 BR 112019000837 A2 BR112019000837 A2 BR 112019000837A2 BR 112019000837 A BR112019000837 A BR 112019000837A BR 112019000837 A BR112019000837 A BR 112019000837A BR 112019000837 A2 BR112019000837 A2 BR 112019000837A2
Authority
BR
Brazil
Prior art keywords
cell mimetic
cells
mimetic cells
cell
methods
Prior art date
Application number
BR112019000837A
Other languages
English (en)
Inventor
Fussenegger Martin
Xie Mingqi
Original Assignee
Eth Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16180000.8A external-priority patent/EP3272877A1/en
Application filed by Eth Zuerich filed Critical Eth Zuerich
Publication of BR112019000837A2 publication Critical patent/BR112019000837A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Emergency Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)

Abstract

a presente invenção se refere a células miméticas de célula ß. métodos para produzir células miméticas de célula ß, assim como métodos para uso de células miméticas de célula ß como um medicamento e métodos para uso de células miméticas de célula ß para a prevenção, retardo de progressão ou tratamento de uma doença metabólica em um indivíduo também são fornecidos.
BR112019000837A 2016-07-18 2017-07-17 células miméticas de célula b BR112019000837A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16180000.8A EP3272877A1 (en) 2016-07-18 2016-07-18 B-cell-mimetic cells
EP16200258 2016-11-23
PCT/EP2017/067981 WO2018015330A1 (en) 2016-07-18 2017-07-17 B-cell-mimetic cells

Publications (1)

Publication Number Publication Date
BR112019000837A2 true BR112019000837A2 (pt) 2019-10-01

Family

ID=59564137

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019000837A BR112019000837A2 (pt) 2016-07-18 2017-07-17 células miméticas de célula b

Country Status (13)

Country Link
US (1) US20190282710A1 (pt)
EP (1) EP3485040B1 (pt)
JP (1) JP2019520837A (pt)
KR (1) KR20190026786A (pt)
CN (1) CN109563487A (pt)
AU (1) AU2017300590A1 (pt)
BR (1) BR112019000837A2 (pt)
CA (1) CA3030642A1 (pt)
IL (1) IL264169A (pt)
MX (1) MX2019000677A (pt)
SG (1) SG11201811763SA (pt)
WO (1) WO2018015330A1 (pt)
ZA (1) ZA201900891B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022145420A1 (pt) * 2020-12-28 2022-07-07
EP4268856A1 (en) * 2020-12-28 2023-11-01 Mochida Pharmaceutical Co., Ltd. Multilayer structure using chemically crosslinked alginic acid
CN116710110A (zh) * 2020-12-28 2023-09-05 持田制药株式会社 新型的多层聚合物涂层交联海藻酸凝胶纤维
WO2024106171A1 (ja) * 2022-11-18 2024-05-23 セルプロジャパン株式会社 細胞培養方法および培養上清の製造方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
WO1992019195A1 (en) 1991-04-25 1992-11-12 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5304473A (en) 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
WO1995005452A2 (en) 1993-08-12 1995-02-23 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
GB9502830D0 (en) * 1995-02-14 1995-04-05 Ecole Polytech Regulation of polypeptide production in cells
CA2223272A1 (en) 1995-05-05 1996-11-07 Ronald Eugene Chance Single chain insulin with high bioactivity
US6054142A (en) 1996-08-01 2000-04-25 Cyto Therapeutics, Inc. Biocompatible devices with foam scaffolds
US6303136B1 (en) 1998-04-13 2001-10-16 Neurotech S.A. Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane
WO2000004171A1 (en) * 1998-07-15 2000-01-27 Wisconsin Alumni Research Foundation Treatment of diabetes with synthetic beta cells
EP1274464B1 (en) * 2000-03-13 2011-09-21 Engene, Inc. Compositions and methods for regulated protein expression in gut
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
US7790690B2 (en) * 2000-10-11 2010-09-07 U.S. Department Of Veterans Affairs Glucose sensitive regulator of insulin transcription
US20030082511A1 (en) * 2001-09-25 2003-05-01 Brown Steven J. Identification of modulatory molecules using inducible promoters
US7141240B2 (en) * 2002-03-12 2006-11-28 Cedars-Sinai Medical Center Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
EP1498483A4 (en) * 2002-04-16 2005-12-07 Kyowa Hakko Kogyo Kk ENDOCRINE CELL LINES AND METHOD FOR THEIR USE
WO2004031372A1 (ja) * 2002-10-02 2004-04-15 Naoya Kobayashi グルコース感受性により改変されたインスリンを分泌する不死化肝細胞株
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー／エス 単鎖インシュリン
EP1863840A1 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Pegylated single-chain insulin
CN101212977A (zh) * 2005-06-01 2008-07-02 国际创新生物技术研究所有限公司 葡萄糖可诱导的胰岛素表达和治疗糖尿病的方法
JP2009527526A (ja) 2006-02-21 2009-07-30 ノボ・ノルデイスク・エー／エス 単鎖インスリンのアナログとその製薬的製剤
WO2007104734A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
EP1996223A1 (en) 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
WO2007104736A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
JP2009530243A (ja) 2006-03-13 2009-08-27 ノボ・ノルデイスク・エー／エス アシル化単鎖インスリン
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
NZ588857A (en) 2008-04-22 2012-07-27 Univ Case Western Reserve Isoform-specific insulin analogue for control blood sugar levels
AU2009335713A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation YL-based insulin-like growth factors exhibiting high activity at the insulin receptor
US8697632B2 (en) 2008-12-19 2014-04-15 Indiana University Research And Technology Corporation Amide based insulin prodrugs
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
CN103210082A (zh) * 2010-09-15 2013-07-17 雷蒙特亚特特拉维夫大学有限公司 扩增胰岛β细胞和使其再分化的方法
KR20130097789A (ko) * 2010-10-15 2013-09-03 코넬 유니버시티 내분비, 위장관 또는 자가면역 장애 치료를 위한 조성물 및 방법
AU2015321457A1 (en) * 2014-09-22 2017-04-13 Rensselaer Polytechnic Institute Compositions and methods to modulate cell activity

Also Published As

Publication number Publication date
ZA201900891B (en) 2019-12-18
CN109563487A (zh) 2019-04-02
EP3485040A1 (en) 2019-05-22
CA3030642A1 (en) 2018-01-25
IL264169A (en) 2019-02-28
US20190282710A1 (en) 2019-09-19
EP3485040B1 (en) 2021-04-14
WO2018015330A1 (en) 2018-01-25
KR20190026786A (ko) 2019-03-13
AU2017300590A1 (en) 2019-01-24
SG11201811763SA (en) 2019-02-27
JP2019520837A (ja) 2019-07-25
MX2019000677A (es) 2019-06-10

Similar Documents

Publication Publication Date Title
MX2023001878A (es) Celulas modificadas geneticamente que comprenden un gen humano modificado de la region constante alfa del receptor de celulas t.
BR112018070506A2 (pt) produção isenta de células de ácido ribonucleico
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
BR112017019409A2 (pt) forma cristalina de ribosídeo de nicotinamida
BR112014024494A2 (pt) dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
BR112015005048A2 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
BR112019000837A2 (pt) células miméticas de célula b
BR112015029386A8 (pt) uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit
MX2020002544A (es) Sales de glicopirrolato.
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
EP3277820A4 (en) Methods for producing modified red blood cell compositions, compositions and uses thereof
BR112017016897A2 (pt) cepas fúngicas e métodos de uso
BR112017001550A2 (pt) enxerto de tecido
PH12018501072A1 (en) Modified release orally administered amino acid formulations
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
BR112018008390A2 (pt) composições e métodos para transdução tumoral
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais
BR112014027087A2 (pt) tablete, método para fabricação de um tablete de mesilato de bromocriptina, método para fabricação de um tablete de mesilato de bromocriptina e método de tratamento para melhorar o controle glicêmico de diabetes do tipo 2 em um paciente
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements